NJBIA has joined 12 other organizations to endorse BioNJ’s recommendations to Gov. Phil Murphy for strengthening the life sciences industry.
“The New Jersey Biopharma Industry: A Prescription for Growth” white paper, released Jan. 4, calls for direct state government support of the industry, promotion of life science innovation and investment, retraining workers for manufacturing and R&D jobs that will be critical for the next decade and strengthening New Jersey’s brand.
“We have long recognized that the highly innovative businesses like those in the biotech industry are critical to the long-term health of New Jersey’s economy,” NJBIA President and CEO Michele Siekerka explained. “To create an environment where such businesses can thrive and create good jobs, we will need greater cooperation between business, academia and government. The recommendations in this report are a great place to start as the new administration takes office.”
BioNJ President and CEO Debbie Hart said, “We very much appreciate these leading organizations that came together to show their support of the New Jersey life sciences industry and its impact on the economy. Our intent in developing these recommendations, which were based on broad and deep analysis, as well as widespread input from members of the ecosystem, was to provide a framework upon which to build future policy that will support industry growth. It is our hope that these are recommendations that all policymakers can get behind.”